Syngene has stepped up its efforts to fight COVID-19 by redirecting its scientific and technical capabilities in COVID-19 related areas to help the Indian authorities in its initiatives to combat the spread of the pandemic.
We have set up a COVID-19 testing laboratory at our Bengaluru campus using RT-PCR technology and have started screening samples to support local authorities. To read our press release, click here.
As of August 31st, 2020, we have tested over 50,000 samples.
Watch: How Syngene conducts RT-PCR testing
Recognizing the need to improve first-generation assays and protocols, Syngene has also developed the ELISA (Enzyme Linked Immunosorbent Assay) test kits. ELISA tests measure antibody levels at relatively higher throughput and lower cost per reaction compared to RTP-CR tests. Syngene has entered into a collaboration with HiMedia Laboratories, a bioscience company for commercialization of the ELISA Test kits. HiMedia will manufacture the kits at its facility in Mumbai and distribute it across India.
To read our press release, click here.
None of the current methods effectively serve the need of massive epidemiological surveillance. To make a difference in this area, Syngene has tied-up with the Centre for Cellular and Molecular Biology for jointly developing and validating a high throughput assay using deep sequencing. This model will be able to take 5,000 to 25,000 samples in one run on next generation sequencing (NGS) platforms such as NextSeq and NovaSeq. This method is also expected to be at least 25% less expensive than existing RT-PCR methods.
Proactive testing is a critical element in restraining the spread of the infection around us. By identifying positive cases early on and enabling them to isolate from others, we can restrict further transmission. Testing also provides the basis for identifying primary contacts of an infected person to prevent further spreading of the infection.